Asthma is a heterogeneous inflammatory disorder involving multiple immune pathways, frequently presenting alongside comorbidities such as chronic rhinosinusitis with nasal polyps (CRSwNP). Although biologic therapies such as dupilumab have shown clinical efficacy, the molecular mechanisms underlying variable treatment responses remain poorly understood. This study aimed to characterize transcriptomic patterns that distinguish asthmatic patients from healthy controls and to evaluate transcriptomic changes induced by dupilumab. Whole-blood RNA-seq was performed in 66 samples, 18 patients (G0) with severe asthma before and after 6 months of dupilumab treatment compared with 30 non-asthmatic controls. Differentially expressed genes (DEGs) were identified and validated by quantitative PCR (qPCR). Clinical responses were assessed using the FEV1, Exacerbations, Oral corticosteroids, Symptoms (FEOS) score and the Sino-Nasal Outcome Test-22 (SNOT-22). A total of 1124 DEGs were identified, distinguishing asthmatic patients from controls. Notably, ABCC1, CYP4F12, FBN1, IKZF2, and RAB44 were differentially expressed across all patients’ subgroups and are proposed as putative general disease biomarkers. Unsupervised machine learning analysis of pre- vs. post-dupilumab transcriptomic profiles identified two distinct patient subgroups within G0, here termed G1 and G2. When comparing baseline vs. post-treatment samples in the overall cohort (G0), only 12 DEGs were identified. In contrast, stratified analysis revealed 1288 DEGs in G1 and 354 DEGs in G2, suggesting divergent molecular response to treatment. Additionally, baseline expression of DIXDC1 was identified as a predictor of CRSwNP non-super-responders. By applying unsupervised machine learning to transcriptomic profiles, this exploratory study identifies two distinct endotypes with divergent molecular mechanisms of response to dupilumab, supporting a precision medicine approach to biologic therapy in severe asthma.
Moreno‐Jimenez et al. (Wed,) studied this question.